Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-77 |
Sentence |
denotes |
Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia |
T2 |
79-93 |
Sentence |
denotes |
To the editor, |
T3 |
94-247 |
Sentence |
denotes |
Superinfections, including invasive pulmonary aspergillosis (IPA), are well-known complications of severe viral pneumonia in critically ill patients [1]. |
T4 |
248-590 |
Sentence |
denotes |
Pathological studies of individuals with severe coronavirus disease 2019 (COVID-19) -associated acute respiratory distress syndrome reported diffuse alveolar damage combined with intra-alveolar neutrophilic infiltration and vascular congestion, assuming an impaired mucociliary activity that might pave the way for secondary infections [2,3]. |
T5 |
591-769 |
Sentence |
denotes |
Our report of two critically ill patients suggests that IPA might be a relevant complication of severe COVID-19 pneumonia in analogy to experiences in severe influenza pneumonia. |
T6 |
770-1063 |
Sentence |
denotes |
Both individuals were without typical risk factors for IPA, e.g. steroid medication or other immunospuppression, and were admitted from a secondary-care hospital with pneumonia caused by COVID-19 to our intensive care unit (ICU) after progression to severe acute respiratory distress syndrome. |
T7 |
1064-1436 |
Sentence |
denotes |
In the initial bronchoalveolar lavage of both patients only COVID-19 was found (PCR negative for influenza virus and respiratory syncytial virus); a follow-up bronchoalveolar lavage because of ongoing fever a few days later (days 5 and 6 after ICU admission) showed elevated galactomannan and growth of Aspergillus fumigatus in standard culture, suggesting IPA (Table 1 ). |
T8 |
1437-1586 |
Sentence |
denotes |
All patients received a chest computed tomography scan before ICU admittance with typical signs for COVID-19 pneumonia but no specific signs for IPA. |
T9 |
1587-1661 |
Sentence |
denotes |
Follow-up computed tomography scans were not performed for safety reasons. |
T10 |
1662-1750 |
Sentence |
denotes |
Table 1 Results of galactomannan (bronchoalveolar lavage and serum) and standard culture |
T11 |
1751-1849 |
Sentence |
denotes |
Patient 1(80 years, male, suspected pulmonary fibrosis) Patient 2(70 years, male, no risk factors) |
T12 |
1850-1905 |
Sentence |
denotes |
Galactomannan from BAL (ODI; normal range <1.0) 6.3 6.1 |
T13 |
1906-1964 |
Sentence |
denotes |
Galactomannan from serum (ODI; normal range <0.5) 1.5 <0.5 |
T14 |
1965-2025 |
Sentence |
denotes |
Standard culture Aspergillus fumigatus Aspergillus fumigatus |
T15 |
2026-2069 |
Sentence |
denotes |
SARS-CoV-2 (at follow up) positive positive |
T16 |
2070-2114 |
Sentence |
denotes |
Laboratory parameters, mean at IPA diagnosis |
T17 |
2115-2134 |
Sentence |
denotes |
CRP (mg/dL) 26 5.1 |
T18 |
2135-2155 |
Sentence |
denotes |
IL-6 (pg/mL) 460 82 |
T19 |
2156-2176 |
Sentence |
denotes |
PCT (ng/mL) 3.7 0.4 |
T20 |
2177-2204 |
Sentence |
denotes |
D-Dimer (μg/L) 4820 14 151 |
T21 |
2205-2223 |
Sentence |
denotes |
LDH (U/L) 481 530 |
T22 |
2224-2258 |
Sentence |
denotes |
Leucocyte count (G/L) 10.38 14.55 |
T23 |
2259-2280 |
Sentence |
denotes |
Lymphocytes (%) 15 7 |
T24 |
2281-2302 |
Sentence |
denotes |
Renal failure Yes Yes |
T25 |
2303-2368 |
Sentence |
denotes |
Classical risk factors for invasive pulmonary aspergillosis No No |
T26 |
2369-2573 |
Sentence |
denotes |
Abbreviations: BAL, bronchoalveolar lavage; CRP, C-reactive protein; IL-6, interleukin 6; IPA, invasive pulmonary aspergillosis; LDH, lactate dehydrogenase; ODI, optical density index; PCT, procalcitonin. |
T27 |
2574-2779 |
Sentence |
denotes |
The time-point of IPA diagnosis is in line with previous studies that demonstrated a median time to IPA diagnosis between 3 and 9 days after ICU admission of patients with severe influenza pneumonia [1,3]. |
T28 |
2780-2863 |
Sentence |
denotes |
In these patients also, high incidence and mortality rates could be observed [1,3]. |
T29 |
2864-2982 |
Sentence |
denotes |
Both patients in our report died as the result of ongoing acute respiratory distress syndrome with multiorgan failure. |
T30 |
2983-3114 |
Sentence |
denotes |
Growth of Aspergillus spp. in a respiratory culture from an ICU patient is often interpreted as colonization rather than infection. |
T31 |
3115-3268 |
Sentence |
denotes |
Other typical diagnostics for IPA, such as biopsy or imaging techniques, may be more challenging in critically ill COVID-19 patients for several reasons. |
T32 |
3269-3441 |
Sentence |
denotes |
Therefore, additional testing of bronchoalveolar lavage specimens for galactomannan is easy, and the specificity of an ODI cut-off of >1·0 is about 90% to detect IPA [4,5]. |
T33 |
3442-3532 |
Sentence |
denotes |
Early and sufficient antifungal medication is the cornerstone for effective IPA treatment. |
T34 |
3533-3724 |
Sentence |
denotes |
Our patients were treated with liposomal amphotericin-B (3 mg/kg) because of multiorgan failure including hepatic failure; however, voriconazole and isavuconazole are sufficient alternatives. |
T35 |
3725-3828 |
Sentence |
denotes |
In conclusion, COVID-19-associated IPA may lead to a poor outcome even in immune competent individuals. |
T36 |
3829-4009 |
Sentence |
denotes |
Further studies are needed to indicate if COVID-19-associated invasive pulmonary aspergillosis is a relevant complication in critically ill patients with severe COVID-19 pneumonia. |
T37 |
4011-4036 |
Sentence |
denotes |
Transparency declarations |
T38 |
4037-4151 |
Sentence |
denotes |
None of the authors has any potential financial or non-financial conflicts of interest related to this manuscript. |
T39 |
4152-4244 |
Sentence |
denotes |
None of the authors has received any funding or financial support regarding this manuscript. |
T40 |
4245-4305 |
Sentence |
denotes |
The manuscript has not been submitted or accepted elsewhere. |
T41 |
4306-4372 |
Sentence |
denotes |
All authors fulfil the criteria given in the authorship paragraph. |
T42 |
4373-4469 |
Sentence |
denotes |
No writing assistance other than copy editing was provided in the preparation of the manuscript. |
T43 |
4471-4487 |
Sentence |
denotes |
Research funding |
T44 |
4488-4507 |
Sentence |
denotes |
Nothing to declare. |
T45 |
4509-4533 |
Sentence |
denotes |
Employment or leadership |
T46 |
4534-4553 |
Sentence |
denotes |
Nothing to declare. |
T47 |
4554-4637 |
Sentence |
denotes |
Tobias Lahmer received travel grants from 10.13039/100004319Pfizer, Gilead and MSD. |